Drug intelligence / Profile preview

Lactobacillus casei BLn2401

Development stage: Unknown
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus casei BLn2401 is a specific probiotic strain characterized as an immunobiotic for its potential to modulate the immune system through the gut-immune axis. In clinical research, it is utilized as a component of a multi-strain probiotic consortium (often alongside Lactobacillus salivarius BL2201 and Bifidobacterium breve BL3406) for the adjunctive treatment of newly diagnosed rheumatoid arthritis (RA). The strain functions by modulating the gut microbiota, which in turn influences systemic inflammation, leading to significant reductions in disease activity scores (DAS28), inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and patient-reported pain. When used as a supplement to conventional disease-modifying antirheumatic drugs (cDMARDs), it has been shown to enhance remission rates and reduce corticosteroid dependence.

Other names: L. casei BLn2401

Beyond the preview

Go deeper on Lactobacillus casei BLn2401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus casei BLn2401.

Explore the full profile